A PYMNTS Company

US: Allergan-Pfizer $113 billion deal could be biggest merger this year

By  |  October 29, 2015

Botox maker Allergan confirmed Thursday that it was in early talks to combine with drug giant Pfizer Inc. in a deal that, if completed, would cap a remarkable spree of mergers this year that’s roiling the healthcare industry.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Allergan, a Dublin, Ireland-based firm with sizable operations in Irvine, said in a statement that it was approached by Pfizer and the discussions were “friendly,” but cautioned there was “no certainty” the talks would lead to a merger.

    Allergan also declined comment on any possible terms of a deal. Allergan had a total stock-market value of $113 billion as of Wednesday’s close, so a Pfizer acquisition likelywould have a price tag well above that figure.

    That would be the biggest deal of a year in which companies throughout the healthcare industry have joined forces to reposition themselves as various market and government forces, notably the Affordable Care Act, have changed the growth outlook for the firms’ revenues and profits.

    Full content: CNBC

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.